Neuromodulation in Patients With Neuropathic Pain and Depression.

Inclusion Criteria:

• Central or peripheral neuropathic pain
• Chronic pain (present for more than 6 months) with intensity greater than or equal to 4/10 on the numerical scale
• Pain present on a daily or near-daily basis (at least 4 days a week)
• Patient not completely relieved by recommended drug treatments for first- andsecond-line neuropathic pain
• Stable analgesic treatment (no new treatment or dosage adjustment) for at least onemonth, and will not need to be modified for the duration of the study.
• Patient with a depressive episode characterized according to DSM V criteria
• Indication for motor cortex rTMS by a neurologist
• Patient can be followed for the entire duration of the study
• Patient having received informed consent to participate in the study, and havingco-signed a consent form with the investigator
• Member or beneficiary of a social security scheme

Exclusion Criteria:

• Industrial accident or litigation
• Contraindication to rTMS or MRI (seismotherapy treatment since the previous month;epilepsy and/or history of epilepsy; history of head trauma; neurosurgical lesion;intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulinpump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia)
• Drug or psychoactive substance abuse
• Neuropathic pain in the context of a progressive pathology (HIV, cancer, systemicdisease disease)
• Presence of other pain more severe than that justifying inclusion
• Patient unable to understand informed consent
• Patient unwilling or unable to stop treatments prohibited during the study
• Patient participating in another research protocol involving a drug within the 30 daysprior to inclusion
• Patient deprived of liberty or under legal protection (guardianship, curatorship,safeguard of justice safeguard, family safeguard)
• Minor patient